Prostate-specific antigen screening, why have the guidelines changed?

References

• Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, et al. Cancer incidence, mortality and prevalence worldwide, GLOBOCAN 2002, American Cancer Society. Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Cancer facts 2012. Available from: www.cancer.org
   Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics,2012. CA Cancer J Clin 2012;62:220-41
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65(1):124-37
   PubMed Web of Science ®Google Scholar
• Committee for Establishment of the Guidelines on Screening for Prostate Cancer; Japanese Urological Association. Updated Japanese urological association guidelines on PSA-based screening for prostate cancer in 2010. Int J Urol 2010;17(10):830-8
   PubMed Web of Science ®Google Scholar
• Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190(2):419-26
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279(19):1542-7
   PubMed Web of Science ®Google Scholar
• Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen Level ≤4.0 ng/ml. N Engl J Med 2004;350(22):2239-46
   PubMed Web of Science ®Google Scholar
• Aus G, Bergdahl S, Lodding P, et al. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol 2007;51(3):659-64
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Carlsson S, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European randomized study of screening for prostate cancer (ERSPC). Eur Urol 2012;62(5):745-52
   PubMed Web of Science ®Google Scholar
• Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000;88(10):2398-424
   PubMed Web of Science ®Google Scholar
• Bouchardy C, Fioretta G, Rapiti E, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008;123(2):421-9
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360(13):1310-19
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate cancer screening in the randomized Prostate, Lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104(2):125-32
   PubMedGoogle Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366(11):981-90
   PubMed Web of Science ®Google Scholar
• Zappa M, Puliti D, Hugosson J, et al. A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality. Eur Urol 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014; S0140-6736(14)60525-0
   PubMed Web of Science ®Google Scholar
• Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101(6):374-83
   PubMedGoogle Scholar
• Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009;101(19):1325-9
   PubMedGoogle Scholar
• Godtman RA, Holmberg E, Khatami A, et al. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol 2013;63(1):101-7
   PubMed Web of Science ®Google Scholar
• Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ 2012;344:d7894
   PubMedGoogle Scholar
• Loeb S, van den Heuvel S, Zhu X, et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012;61(6):1110-14
   PubMed Web of Science ®Google Scholar
• Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2013;189(1 Suppl):S12-17; discussion S17-8
   PubMed Web of Science ®Google Scholar
• Keto CJ, Freedland SJ. A risk-stratified approach to prostate-specific antigen screening. Eur Urol 2011;59(4):506-8
   PubMed Web of Science ®Google Scholar
• Howard K, Barratt A, Mann GJ, et al. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices. Arch Intern Med 2009;169(17):1603-10
   PubMedGoogle Scholar
• Gulati R, Wever EM, Tsodikov A, et al. What if i don’t treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev 2011;20(5):740-50
   PubMed Web of Science ®Google Scholar
• Zhang J, Denton BT, Balasubramanian H, et al. Optimization of PSA screening policies: a comparison of the patient and societal perspectives. Med Decis Making 2012;32(2):337-49
   PubMed Web of Science ®Google Scholar
• Drazer MW, Huo D, Schonberg MA, et al. Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 2011;29(13):1736-43
   PubMed Web of Science ®Google Scholar
• U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149(3):185-91
   PubMed Web of Science ®Google Scholar
• Ankerst DP, Hoefler J, Bock S, et al. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low vs high-grade prostate cancer. Urology 2014;83(6):1362-7
   PubMed Web of Science ®Google Scholar
• Grummet JP, Weerakoon M, Huang S, et al. Sepsis and ’superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int 2014;114(3):384-8
   PubMed Web of Science ®Google Scholar
• Porpiglia F, Russo F, Manfredi M, et al. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? J Urol 2014;S0022-5347(14):00052-4
   Google Scholar
• van Hove A, Savoie PH, Maurin C, et al. Comparison of image-guided targeted biopsies versus systematic randomized biopsies in the detection of prostate cancer: a systematic literature review of well-designed studies. World J Urol 2014;32(4):847-58
   PubMed Web of Science ®Google Scholar
• Radtke JP, Kuru TH, Boxler S, et al. Comparative analysis of transperineal template-saturation prostate biopsy versus MRI-targeted biopsy with MRI-US fusion-guidance. J Urol. [Epub ahead of print]
   Google Scholar
• Da Rosa MR, Milot L, Sugar L, et al. A prospective comparison of MRI-US fused targeted biopsy versus systemic ultrasound-guided biopsy for detecting clinically significant prostate cancer in patients on active surveillance. J Magn Reson Imaging 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Mearini L, Ferri C, Lazzeri M, et al. Evaluation of prostate-specific antigen isoform p2PSA and its derivates, %p2PSA, prostate health index and prostate dimension-adjusted related index in the detection of prostate cancer at first biopsy: an exploratory, prospective study. Urol Int 2014;93(2):135-45
   PubMed Web of Science ®Google Scholar
• Loeb S, Catalona WJ. The prostate health index: a new test for the detection of prostate cancer. Ther Adv Urol 2014;6(2):74-7
   PubMedGoogle Scholar
• Nakai Y Anai S, Kuwada M, et al. Photodynamic diagnosis of shed prostate cancer cells in voided urine treated with 5-aminolevulinic acid. BMC Urol 2014;14(1):59
   PubMed Web of Science ®Google Scholar